Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics Statistics
Share Statistics
Akebia Therapeutics has 261.23M shares outstanding. The number of shares has increased by 4.21% in one year.
| Shares Outstanding | 261.23M |
| Shares Change (YoY) | 4.21% |
| Shares Change (QoQ) | 3.75% |
| Owned by Institutions (%) | 32.25% |
| Shares Floating | 250.51M |
| Failed to Deliver (FTD) Shares | 26.41K |
| FTD / Avg. Volume | 0.75% |
Short Selling Information
The latest short interest is 17.99M, so 8.25% of the outstanding shares have been sold short.
| Short Interest | 17.99M |
| Short % of Shares Out | 8.25% |
| Short % of Float | 8.67% |
| Short Ratio (days to cover) | 8.43 |
Valuation Ratios
The PE ratio is -5.77 and the forward PE ratio is -16.96. Akebia Therapeutics's PEG ratio is -0.32.
| PE Ratio | -5.77 |
| Forward PE | -16.96 |
| PS Ratio | 2.5 |
| Forward PS | 0.5 |
| PB Ratio | -8.15 |
| P/FCF Ratio | -9.85 |
| PEG Ratio | -0.32 |
Enterprise Valuation
Akebia Therapeutics Inc. has an Enterprise Value (EV) of 293.71M.
| EV / Earnings | -4.23 |
| EV / Sales | 1.83 |
| EV / EBITDA | -21.41 |
| EV / EBIT | -5.82 |
| EV / FCF | -7.22 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of -0.07.
| Current Ratio | 1.41 |
| Quick Ratio | 1.21 |
| Debt / Equity | -0.07 |
| Total Debt / Capitalization | -7.77 |
| Cash Flow / Debt | -11.46 |
| Interest Coverage | -2.78 |
Financial Efficiency
Return on equity (ROE) is 1.41% and return on capital (ROIC) is 110.59%.
| Return on Equity (ROE) | 1.41% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | 110.59% |
| Revenue Per Employee | $884,972.38 |
| Profits Per Employee | $-383,480.66 |
| Employee Count | 181 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 3.89 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 4.92% in the last 52 weeks. The beta is 0.94, so Akebia Therapeutics's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | 4.92% |
| 50-Day Moving Average | 2.08 |
| 200-Day Moving Average | 1.65 |
| Relative Strength Index (RSI) | 45.93 |
| Average Volume (20 Days) | 3.5M |
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 160.18M and earned -69.41M in profits. Earnings per share was -0.33.
| Revenue | 160.18M |
| Gross Profit | 97M |
| Operating Income | -50.47M |
| Net Income | -69.41M |
| EBITDA | -13.72M |
| EBIT | -50.47M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 51.87M in cash and 3.55M in debt, giving a net cash position of 48.32M.
| Cash & Cash Equivalents | 51.87M |
| Total Debt | 3.55M |
| Net Cash | 48.32M |
| Retained Earnings | -1.68B |
| Total Assets | 220.67M |
| Working Capital | 32.92M |
Cash Flow
In the last 12 months, operating cash flow was -40.66M and capital expenditures -33K, giving a free cash flow of -40.69M.
| Operating Cash Flow | -40.66M |
| Capital Expenditures | -33K |
| Free Cash Flow | -40.69M |
| FCF Per Share | -0.19 |
Margins
Gross margin is 60.56%, with operating and profit margins of -31.51% and -43.33%.
| Gross Margin | 60.56% |
| Operating Margin | -31.51% |
| Pretax Margin | -43.33% |
| Profit Margin | -43.33% |
| EBITDA Margin | -8.57% |
| EBIT Margin | -31.51% |
| FCF Margin | -25.4% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -17.19% |
| FCF Yield | -8.11% |
Analyst Forecast
The average price target for AKBA is $6.75, which is 251.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.75 |
| Price Target Difference | 251.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -9.39 |
| Piotroski F-Score | 3 |